Nxera Pharma Valuation Multiples

Nxera Pharma Overview

About Nxera Pharma

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

Founded

1990

HQ

Employees

181

Website

nxera.life

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $206M

EBITDA: ($9M)

EV

$817M

Valuation Multiples

Multiples.vc

Start free trial

Nxera Pharma Financials

Nxera Pharma reported last 12-month revenue of $206M and negative EBITDA of ($9M).

In the same LTM period, Nxera Pharma generated ($9M) in EBITDA losses and had net loss of ($55M).

Nxera Pharma P&L

In the most recent fiscal year, Nxera Pharma reported revenue of $193M and EBITDA of ($20M).

Nxera Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Nxera Pharma Stock Performance

Nxera Pharma has current market cap of $584M, and enterprise value of $817M.

Nxera Pharma's stock price is $6.45.

Nxera Pharma Valuation Multiples

Nxera Pharma trades at 4.0x EV/Revenue multiple, and (87.8x) EV/EBITDA.

Nxera Pharma Financial Valuation Multiples

As of April 11, 2026, Nxera Pharma has market cap of $584M and EV of $817M.

Equity research analysts estimate Nxera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Nxera Pharma has a P/E ratio of (10.6x).

Nxera Pharma Margins & Growth Rates

Nxera Pharma's revenue in the last 12 month grew by 17%.

Nxera Pharma's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.0M for the same period.

Nxera Pharma's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nxera Pharma's rule of X is 89% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Nxera Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Nxera Pharma M&A Activity

Nxera Pharma acquired XXX companies to date.

Last acquisition by Nxera Pharma was on XXXXXXXX, XXXXX. Nxera Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Nxera Pharma Investment Activity

Nxera Pharma invested in XXX companies to date.

Nxera Pharma made its latest investment on XXXXXXXX, XXXXX. Nxera Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).